Key Points {#FPar1}
==========

Assessment of optic nerve function is a readily accessible target for evaluating MS therapies that aim to restore neurological function. This study evaluated whether high-dose pharmaceutical-grade biotin (hdPB; MD1003) could improve visual function in patients with MS who had chronic optic neuritis (ON)MD1003 did not improve visual function compared with placebo in the subset of patients with fixed visual loss following an acute episode of ON; however, there were trends towards improvement in a number of measures of visual function in patients with progressive chronic optic neuropathyThese results are consistent with recent data that showed that MD1003 can decrease progression and improving walking disability in patients with progressive MS. The treatment was overall well tolerated

Introduction {#Sec1}
============

Multiple sclerosis (MS) is a frequent and disabling neurological disease characterized by multifocal myelin destruction in the central nervous system. Most patients with MS experience an initial period of relapsing--remitting disease (RRMS) followed later by a progressive disease course (secondary progressive MS; SPMS) \[[@CR1]\]. Approximately 15% of patients experience progressive disease from onset (primary progressive MS; PPMS) \[[@CR1], [@CR2]\]. Progressive MS, either SPMS or PPMS, can be further categorized as active or non-active depending on the presence of superimposed inflammatory activity \[[@CR3]\]. There are currently no disease-modifying therapies approved for the treatment of non-active progressive MS.

Among the potential causes of progressive axonal degeneration in progressive MS are chronic demyelination and mitochondrial dysfunction, which both lead to a state of virtual hypoxia \[[@CR4]--[@CR6]\]. We recently reported the results of a randomized, double-blind, placebo-controlled study that showed that MD1003 (high-dose pharmaceutical-grade biotin \[hdPB\]) achieved sustained reversal of MS-related disability in patients with progressive MS without activity in the last 2 years before inclusion \[[@CR7]\]. Biotin is a cofactor for acetyl-CoA carboxylase, the rate-limiting enzyme that generates malonyl-CoA, the two-carbon building block for fatty acid synthesis, which is an essential component of myelin \[[@CR9], [@CR10]\]. Biotin is also a cofactor for three enzymes that generate intermediates for the tricarboxylic acid cycle: pyruvate carboxylase, 3-methylcrotonyl-CoA carboxylase, and propionyl-CoA carboxylase \[[@CR9]\]. Therefore, the improvements in disability seen in patients with progressive MS treated with hdPB may be due to an increase in the supply of precursors for fatty acid and myelin synthesis and/or replenishment of the pool of adenosine triphosphate (ATP) in hypoxic neurons \[[@CR7], [@CR8]\].

Acute optic neuritis (ON) is an inflammatory and demyelinating disorder of the optic nerve that occurs in up to 50% of patients with MS and is the first symptom in up to 20% \[[@CR11], [@CR12]\]. Optic neuritis leads to loss of vision and typically presents as an acute monocular loss of vision, though it can affect both eyes either simultaneously or sequentially \[[@CR13], [@CR14]\]. Symptoms of ON include reduced visual acuity (VA), periocular pain (especially during eye movements), reduced contrast sensitivity, dysfunction of color vision, and visual field defects \[[@CR11], [@CR12]\]. Vision loss typically develops over a period of hours or days and peaks within 1 or 2 weeks \[[@CR11]\]. Most patients regain VA within 6 months, though visual contrast often remains impaired \[[@CR15], [@CR16]\]. In a minority of cases, VA remains low more than 6 months after an acute ON. This type of chronic visual loss is referred to as 'sequelae of an acute optic neuritis' (AON). In rare cases, visual loss becomes slowly progressive, so-called 'progressive optic neuropathy' (PON) \[[@CR17]--[@CR19]\].

Patients with optic nerve injury represent a good target group to evaluate the efficacy of drugs aimed at restoring neurological function in patients with MS, as the optic nerves are accessible to precise and quantitative measures. Visual function can readily be assessed using ETDRS (Early Treatment Diabetic Retinopathy Study) logarithm of the minimum angle of resolution (logMAR) charts at high and low contrast to determine VA \[[@CR20]\] and automated perimetry to examine visual field defects \[[@CR21]\]. Optic nerve function can be assessed by recording visual evoked potentials (VEPs) \[[@CR22]\] and the pathological changes seen in the thickness of the retinal nerve fiber layer (RNFL) can be accurately quantified via optical coherence tomography (OCT).

In the initial open-label study of MD1003 in patients with progressive MS, four patients with a progressive visual loss caused by chronic ON (PON type) had an improvement in VA within 6 months of treatment with hdPB \[[@CR23]\]. The aim of the MS-ON study was to confirm these initial observations in patients with either AON or PON.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

MS-ON was a 6-month double-blind, multi-center, randomized, placebo-controlled study followed by a 6-month extension phase during which all patients received MD1003 \[Online Resources 1, see electronic supplementary material (ESM)\]. The study was conducted between October 2013 and September 2015 at 19 sites in France and one site in the United Kingdom.

Participants {#Sec4}
------------

Eligible patients were aged 18--75 years old with a diagnosis of MS fulfilling the 2010 McDonald criteria \[[@CR24]\], uni- or bilateral optic neuropathy with VA in the worst eye of ≤ 5/10 (decimal scale; 20/40 in US customary units) confirmed at 6 months, and evidence of worsening VA during the last 3 years (defined as a change in VA of ≥ 1/10 points or more than one line). In AON, VA had to remain stable at least in the 6 months prior to inclusion. In PON, progressive visual loss had to have been noted at two different visits in the previous 3 years.

Key exclusion criteria included relapse of ON within 3 months before inclusion; other concomitant ocular conditions (glaucoma, cataract, retinopathy, anterior uveitis, myopia \> 7 dioptrics, intraocular pressure \> 20 mmHg, amblyopia, retinal or optic head abnormalities); bilateral VA \< 1/20, visual impairment caused by ocular flutter or nystagmus; or normal RNFL. Patients who were treated with fampridine initiated \< 1 month prior to inclusion or any other new medication for MS (immunomodulators and immunosuppressive agents) initiated \< 3 months prior to inclusion were also excluded. Full eligibility criteria are shown in Online Resource 2 (see ESM).

Intervention {#Sec5}
------------

In the placebo-controlled phase of the trial, patients were randomized 2:1 to either MD1003 (oral biotin 300 mg/day administered as 100-mg capsules three times daily) or placebo. Placebo capsules were identical to hdPB capsules except for an additional 100 mg lactose excipient in place of hdPB. Randomization was performed with a computer-generated sequence provided by an independent contract research organization. Each participating hospital pharmacy was provided with a block of six treatment units (four active and two placebo treatments in random order). No stratification was performed.

Patients and investigators were masked to the assigned treatment during the placebo-controlled phase and remained blinded during the extension phase as to which treatment was administered during the first phase. The treating neurologist was different from the evaluating ophthalmologist.

All usual treatments were allowed during the study providing these were initiated as described in the exclusion criteria.

Assessments {#Sec6}
-----------

Impairment of the optic nerve was assessed by VA in each eye separately using ETDRS logMAR charts presented with standard illumination \[[@CR20]\]. Visual acuity was performed at 100 and 5% contrast at screening, baseline, and every 3 months.

In addition, VEPs, automated perimetry, and OCT including RNFL thickness was performed. Assessment of VEPs was conducted at baseline and months 6 and 12 according to guidelines of the International Society for Clinical Electrophysiology of Vision \[[@CR25]\]. Improvement was defined as (i) the reappearance of a P100 wave not visible in a previous examination or (ii) improvement of the P100 wave latency of at least 10 ms. Visual field analyses were performed using standard automated perimetry at screening, baseline, and months 6 and 12. Spectral domain OCT was conducted at baseline and months 6 and 12 and RNFL thickness and macular volume were recorded at these time points.

Health outcome assessments consisted of the clinical global impression scale evaluated by the patient (SGI) and by the clinician (CGI) at months 6 and 12 and the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire and the National Eye Institute 25-Item Visual Function Questionnaire (NEIVFQ-25) assessed at baseline, month 6, and month 12.

A detailed description of all the efficacy and health outcome assessments used in this study is provided in the Online Resources (Online Resources 3, see ESM).

Study Objectives {#Sec7}
----------------

The primary endpoint of the study was the mean absolute change from baseline to month 6 of VA in the selected eye as measured by best-corrected VA (logMAR) at 100% contrast. The selected eye was the eye with the worst VA at baseline and with evidence of worsening during the past 3 years.

Secondary endpoints were assessed at month 6 and comprised the proportion of patients with improvement of VA of the selected eye of ≥ 0.3 logMAR at 100% contrast or improvement of binocular VA from \< 70 to ≥ 70/100 at 100% contrast; the proportion of eyes with reappearance of P100 waves or improvement of P100 latencies of ≥ 10 ms; the mean change from baseline in selected P100 latencies and amplitudes (all eyes); CGI and SGI; and the mean change from baseline in NEIVFQ-25 composite score and MSQOL-54 composite score and sub-scores.

Exploratory analyses assessed at month 6 consisted of the mean change from baseline in logMAR at 100 and 5% contrast in non-selected eyes, all eyes, and binocular vision (at 100% contrast only); the proportion of patients with improvement at 5% contrast in at least one eye of ≥ 0.3, ≥ 0.2, or ≥ 0.1 logMAR; and the mean change from baseline of the mean deviation in visual fields, RNFL thickness, temporal RNFL values, and macula volume.

Safety was investigated by comparing the incidence of adverse events (AEs) and laboratory/electrocardiogram findings between study arms.

Statistical Considerations {#Sec8}
--------------------------

Sample size determination was based on limited data. In four patients with progressive ON treated with hdPB 300 mg/day \[[@CR23]\], a mean improvement of VA on treatment of 0.423 logMAR (SD 0.29) was observed. VA in patients with ON after 6 months of chronic visual loss does not typically improve spontaneously \[[@CR26]\]. Therefore, assuming a conservative mean improvement of 0.3 logMAR for the patients in the MD1003 arm and a mean change with placebo of 0.0 logMAR, and a common standard deviation of 0.29, 70 patients in the MD1003 arm and 35 patients in the placebo arm (total sample size of 105) were required to provide 99% power to detect a difference between arms, at a 0.05 two-sided significance level.

Quantitative data were summarized using descriptive statistics and qualitative data using proportions. The intent-to-treat population (ITT) was defined as all randomized patients who received at least one dose of study medication and had at least one baseline VA score. All patients from the ITT population who also had a VA score at month 6 without any major protocol deviations comprised the per-protocol population (PP). The safety population was defined as all patients who received at least one dose of study drug. Baseline values were defined as the last available assessments before or at date of first study drug administration.

The primary endpoint was assessed in the ITT population and differences in the mean absolute change in VA at month 6 between arms were evaluated by an ANCOVA analysis with adjustment for baseline VA. A Welch *t* test and a Wilcoxon--Mann--Whitney test were performed on the primary efficacy endpoint in the ITT population as sensitivity analyses. The primary efficacy analysis was also assessed at months 3 and 12 in the ITT population and in the PP population. Pre-planned subgroup analyses were conducted in subgroups stratified according to PON or AON; baseline binocular VA at 100% contrast \< 70 or ≥ 70/100; and baseline RNFL thickness \< 75 or ≥ 75 μM. Between the two groups, the differences in secondary endpoints were examined using Fisher's exact test for proportions, Mann--Whitney's *U* test for means, and a logistic model using generalized estimating equations. All statistical analyses were two-sided with a significance level of *p* \< 0.05 and were conducted by the Biostatistics Unit of BIOTRIAL using SAS^®^ software 9.3 (SAS Institute Inc., Cary, NC, USA). The Last Observation Carried Forward imputation method was used for missing data.

Results {#Sec9}
=======

Between October 2013 and January 2015, 117 patients were screened, of which 93 met the inclusion criteria and were randomized to MD1003 (*n* = 65; 69.9%) or placebo (*n* = 28; 30.1%; Fig. [1](#Fig1){ref-type="fig"}). Baseline patient demographics and disease characteristics were balanced between study arms (Table [1](#Tab1){ref-type="table"}). Most patients (62; 66.7%) had AON; 31 (33.3%) patients had PON. Fifty-nine patients (63.4%) had RRMS, 14 (15.1%) had PPMS, and 20 (21.5%) had SPMS. Patients were severely impaired as illustrated by low VA and neuro-ophthalmologic measures. Most (61/89; 68.5%) patients did not have identifiable P100 waves as assessed by VEP and the majority (74/81; 84.1%) had a thin (\< 75 µm) RNFL. The distribution of disease-modifying concomitant medications was similar between arms during the placebo-controlled part of the study except for methylprednisolone and natalizumab (Table [1](#Tab1){ref-type="table"}).Fig. 1CONSORT diagram---screening, enrolment, randomization and follow-up of study patients Table 1Baseline demographics and disease characteristics (ITT population)MD1003 (*n* = 65)Placebo (*n* = 28)*p* valueFemale, *n* (%)35 (53.8)15 (53.6)1Age, years, mean (SD)41.6 (10.5)41.1 (10.6)0.795\*\*Duration of MS (SD), years^a^12.6 (9.4)11.3 (8.1)0.705\*\*Relapsing--remitting MS, *n* (%)^f^45 (69.2)14 (50.0)0.101Progressive MS, *n* (%)^f^20 (30.8)14 (50.0)0.101AON, *n* (%)41 (63.1)21 (75.0)0.340PON, *n* (%)24 (36.9)7 (25.0)0.340Mean VA in logMar (SD)^b^0.82 (0.38)0.77 (0.45)0.196\*\*Binocular VA, *n* (%)^b,c^ \< 7021 (39.6)7 (30.4)0.623 ≥ 70--10032 (60.4)16 (69.6)0.506P100 waves, *n* (%)^d^ Absent42 (66.7)19 (73.1)0.815 Present21 (33.3)7 (26.9)0.623RNFL, *n* (%)^e^ \< 75 μM51 (83.6)23 (85.2)0.784 ≥ 75 μM10 (16.4)4 (14.8)1Concomitant DMT (%)46 (70.7)16 (57.1)0.234 Fampridine6 (9.2)2 (7.1)1 Fingolimod10 (15.4)7 (25.0)0.380 Interferon β-1A or β-1B10 (15.4)3 (10.7)0.747 Natalizumab9 (13.8)1 (3.6)0.272 Cyclophosphamide0 (0.0)1 (3.6)0.301 Methylprednisolone12 (18.5)1 (3.6)0.099 Glatiramer acetate9 (13.8)4 (14.3)1 Methotrexate1 (1.5)2 (7.1)0.214 Azathioprine2 (3.1)1 (3.6)1 Mycophenolate mofetil7 (10.8)1 (3.6)0.427*AON* acute optic neuritis, *DMT* disease-modifying therapy, *ITT* intention-to-treat, *ON* optic neuritis, *MS* multiple sclerosis, *PON* progressive optic neuropathy, *RNFL* retinal nerve fiber layer, *SD* standard deviation, *VA* visual acuity*p* values were calculated using Fisher exact test or Mann--Whitney test (\*\*)^a^Time between first appearance of MS and first treatment^b^At 100% contrast; data were missing for: ^c^12 patients in the MD1003 group and five patients in the placebo group, ^d^two patients in each group, ^e^four patients in the MD1003 group and one patient in the placebo group^f^The progressive and relapsing phenotypes relate to the overall patient status whereas the AON/PON classification relates to the optic neuropathy type. The two classifications do not necessarily correlate

Treatment compliance was good during the placebo-controlled part with 67 (72.0%) patients overall achieving compliance rates of ≥ 90%. Mean duration of treatment in the safety population was 5.6 months in both arms. One patient was withdrawn from the study during the placebo-controlled part because of an adverse event (AE)---retinal artery occlusion in the MD1003 arm considered to be possibly treatment related by the Investigator. The remaining 92 patients entered the 6-month extension phase. Treatment compliance was lower during the extension phase with 55 (59.8%) patients overall achieving compliance rates ≥ 90%. The mean (SD) overall duration of treatment during the extension phase was 5.5 (0.6) months. Twelve (23.7%) patients had treatment withdrawal during the extension phase (Fig. [1](#Fig1){ref-type="fig"}).

Primary Efficacy Analysis {#Sec10}
-------------------------

At month 6, the mean (SEM) change in logMAR VA at 100% contrast for the selected eye was − 0.061 (0.026) in the MD1003 arm and − 0.036 (0.035) in the placebo arm (Fig. [2](#Fig2){ref-type="fig"}), indicating an improvement in VA in both arms corresponding to an additional 3.1 letters and 1.8 letters, respectively, on the ETDRS chart. This difference between arms was not significant (mean treatment difference − 0.01983; 95% CI − 0.1085 to 0.0689; *p* = 0.66). At the end of the extension phase (month 12), the mean change in logMAR VA at 100% contrast for the selected eye corresponded to + 4.3 letters in the MD1003 \> MD1003 arm and + 4.0 letters in the placebo \> MD1003 arm.Fig. 2Primary endpoint: mean (± SEM) change from baseline in logMAR at 100% contrast (selected eye) at month 6 (*n* = 93). ITT population. The figure also shows the results of the primary efficacy analysis during the extension phase (month 12; *n* = 92). *ITT* intention-to-treat, *SEM* standard error of the mean

There was no difference between treatment arms in pre-planned subgroup analyses according to fampridine treatment and in patients with \< 70 or ≥ 70/100 binocular VA at 100% contrast at baseline, or in patients with \< 75 or ≥ 75 μM RNFL thickness at baseline. All results were similar when analyzed in the PP population (*n* = 86).

### Subgroup Analyses in Acute Optic Neuritis (AON) and Progressive Optic Neuropathy (PON) {#Sec11}

In patients with PON, the mean (SD) change from baseline in logMAR values at 100% contrast in the selected eye at month 6 was − 0.058 (0.185) in the MD1003 group and + 0.029 (0.176) in the placebo group. This equated to an improvement of + 2.8 letters in the MD1003 group and a worsening of − 1.5 letters in the placebo group (*p* = 0.45) (Fig. [3](#Fig3){ref-type="fig"}a). At month 12, the mean change in logMAR values from baseline corresponded to + 4.6 letters in the MD1003 group and -- 1.2 letters in the placebo group at month 12 (*p* = 0.26). In contrast, there was no difference between treatment groups in patients with AON (Fig [3](#Fig3){ref-type="fig"}b).Fig. 3Pre-planned subgroup analysis of the primary efficacy analysis in patients with **a** progressive optic neuropathy (*n* = 31) and **b** sequelae of an acute optic neuritis (*n* = 62). ITT population. *ITT* intention-to-treat, *SEM* standard error of the mean

Secondary and Exploratory Endpoints {#Sec12}
-----------------------------------

Overall, there were no significant differences between treatment arms for the secondary and exploratory endpoints (Online Resource 4, see ESM). Post hoc analyses according to PON and AON subgroups revealed trends in several secondary endpoints favoring MD1003 over placebo in patients with PON (Fig. [4](#Fig4){ref-type="fig"}), which was not the case in patients with AON. In the PON subgroup, the mean change from baseline to month 6 in logMAR at 5% contrast for all eyes improved in the MD1003 group (+ 3.7 letters) but worsened in the placebo group (− 0.7 letters; Fig. [4](#Fig4){ref-type="fig"}a). MD1003 also appeared to halt the thinning of the RNFL in the PON subgroup during the 6-month placebo-controlled phase (Fig. [4](#Fig4){ref-type="fig"}b). The positive effect of MD1003 on vision in the subgroup of patients with PON was also reflected in the trend towards improvement in vision-associated daily life activities compared with placebo, as assessed by the NEIVFQ-25 questionnaire (Fig. [4](#Fig4){ref-type="fig"}c). It should be noted that, because of the low number of patients in the placebo group (*n* = 7), these positive trends are merely indicative of MD1003 effect.Fig. 4Mean (± SEM) change from baseline to month 6 in **a** logMAR at 5% contrast (all eyes), **b** mean RNFL thickness (all eyes), and **c** NEIVFQ-25 composite score, in patients with progressive optic neuropathy (*n* = 31). ITT population. *ITT* intention-to-treat, *NEIVFQ-25* National Eye Institute 25-Item Visual Function Questionnaire, *RNFL* retinal nerve fiber layer, *SEM* standard error of the mean

There were no notable changes between study arms in the PON subgroup in visual field assessments or VEPs.

Safety {#Sec13}
------

Treatment in both arms was well tolerated. During the placebo-controlled part of the study, a similar proportion of patients experienced an AE in both arms (49 \[75.4%\] in the MD1003 arm and 22 \[78.6%\] patients in the placebo arm; Table [2](#Tab2){ref-type="table"}). Most AEs were mild to moderate in severity (95.4% of patients in the MD1003 arm; 92.9% of patients in the placebo arm). Severe AEs were recorded in three (4.6%) patients in the MD1003 arm (single cases of apparent hyperthyroidism due to the known biotin--thyroid assay interaction, retinal artery occlusion, and back pain) and two (7.1%) patients in the placebo arm (fatigue and gastroenteritis). The only serious AEs to occur in more than one patient were MS-related: MS relapse (symptoms confirmed to be associated with evolution of the disease) occurred in nine (13.8%) MD1003-treated patients and one (3.6%) placebo-treated patient, and MS symptoms (possibly but not necessarily associated with MS) occurred in two MD1003-treated patients. During the extension phase, 32 patients (50.0%) in the MD1003 \> MD1003 arm and 12 patients (42.9%) in the placebo \> MD1003 arm experienced AEs. Again, the only serious adverse events (SAEs) reported in more than one patient were MS-related: MS relapse was recorded in three (4.7%) patients in the MD1003 \> MD1003 group and three (10.7%) patients in the placebo \> MD1003 group. No deaths occurred during the study.Table 2Adverse events reported during the study (safety population)Trial phaseTrial arm 1Trial arm 2*p* value**Double-blind, placebo-controlled phase**MD1003 (*n* = 65)Placebo (*n* = 28)Any AE, *n* (%)49 (75.4)22 (78.6)0.797AEs occurring in ≥ 5% of patients in either group MS relapse9 (13.8)1 (3.6)0.272 Nasopharyngitis8 (12.3)1 (3.6)0.269 Urinary tract infection4 (6.2)1 (3.6)1 Headache3 (4.6)3 (10.7)0.360 Asthenia2 (3.1)2 (7.1)0.581 Gastroenteritis1 (1.5)3 (10.7)0.079 Dizziness2 (7.1) Depression2 (7.1) Anxiety2 (7.1)Any severe AE^a^, *n* (%)3 (4.6)2 (7.1)0.635 Severe AEs occurring in ≥ 1 patient in either group  NoneAny SAE, *n* (%)9 (13.8)3 (10.7)1 SAEs occurring in ≥1 patient in either group  MS relapse9 (13.8)1 (3.6)0.272**Extension phase**MD1003 \> MD1003 (*n* = 64)Placebo \> MD1003 (*n* = 28)Any AE, *n* (%)32 (50.0)12 (42.9)0.651 AEs occurring in ≥ 5% of patients in either group  Headache1 (1.6)3 (10.7)0.082  MS relapse3 (4.7)3 (10.7)0.363  Edema peripheral2 (7.1)  Oropharyngeal pain2 (7.1)Any severe AE^b^, *n* (%)1 (1.6)2 (7.1)0.218 Severe AEs occurring in ≥1 patient in either group  NoneAny SAE, *n* (%)6 (9.4)4 (14.3)0.485 SAEs occurring in ≥1 patient in either group  MS relapse3 (4.7)3 (10.7)0.363*p* values were calculated using Fisher exact test*AE* adverse event, *MS* multiple sclerosis, *SAE* serious adverse event^a^Severe AEs during the placebo-controlled phase were single cases of hyperthyroidism, retinal artery occlusion, back pain, and MS relapse in the MD1003 group and single cases of fatigue and gastroenteritis in the placebo group^b^Severe AEs during the extension phase were a single case of joint dislocation in the MD1003 \> MD1003 group and single cases of headache and MS relapse in the MD1003 \> placebo group

Discussion {#Sec14}
==========

We evaluated the efficacy of MD1003 in MS patients with chronic visual loss in a randomized, double-blind, placebo-controlled, 6-month study involving 93 patients, followed by a 6-month, open-label extension during which all patients received MD1003. Inclusion of both AON and PON allowed us to evaluate whether MD1003 would have efficacy in driving recovery after a relapse (AON) or would more specifically demonstrate efficacy in the progressive disease state (PON).

Overall, the primary objective of study MS-ON was not reached: the improvement in the number of letters read on the ETDRS chart at month 6 was larger with MD1003 (+ 3.1 letters) than with placebo (+ 1.8 letters), but this difference was not statistically significant (*p* = 0.66). There were no significant overall differences between study arms in the secondary endpoints. These results might reflect in part the main limitations of our study. As mentioned earlier, sample size determination was based on limited data and the number of patients randomized was low, especially in the placebo group (*n* = 28). This small sample size limitation was further accentuated by the heterogeneity of the population, which included subsets of patients with two distinct types of ON (AON and PON). The fact that, as an average, placebo-treated patients with AON spontaneously improved during the course of the trial, led to potential underestimation of MD1003 therapeutic effect. In addition, the trial lasted only 6 months, which might have been too short to observe the full extent of MD1003 therapeutic potential.

Interestingly, the pre-planned subgroup analyses in patients with AON or PON revealed two important findings. There was clearly no effect of MD1003 in the subgroups of patients with AON for all measures related to optic nerve involvement. This suggests that MD1003 does not trigger or re-initiate recovery after a relapse in this population and time frame. In contrast, a consistent trend suggesting treatment efficacy was observed in the PON subgroup. This trend favoring MD1003 in patients with PON was observed for VA at 100% contrast, VA at 5% contrast, RNFL, and NEIVFQ-25. We observed no changes in VEPs or visual field in the subgroup of patients with PON. It should be noted that patients recruited to the study had considerable neurodegenerative damage of the optic nerve at baseline as evidenced by the absence of measurable P100 waves in approximately 70% of patients. Patients also had severe impairment of their visual field at baseline. This degree of baseline disability may have precluded any meaningful improvement in these measures of optic nerve function.

The high proportion of patients with AON recruited to the study (63.4% of the overall population) may explain the failure of the study to reach the primary endpoint. In fact, only a relatively small number of patients with PON (*n* = 31) were recruited, reflecting the relative rarity of patients with this condition.

Since MD1003 is believed to target the underlying progressive aspect of MS \[[@CR8]\], patients with PON provide an appropriate model for the assessment of efficacy of MD1003. The trend of efficacy observed in patients with PON is consistent with observations from a pilot open-label study in which VA improved after treatment with hdPB in four patients with PON \[[@CR23]\]. This trend is also in line with the findings of study MS-SPI, which demonstrated that MD1003 significantly improved MS-related disability in patients with a progressive spinal form of MS \[[@CR7]\]. Together, these data are consistent with the proposed mechanism of action for MD1003 in targeting mechanisms to improve neuronal metabolism in context of virtual hypoxia, consistent with the pathophysiology of progressive MS.

The absence of superiority vs placebo in patients with AON suggests that MD1003 does not accelerate spontaneous recovery after an acute optic neuritis in a relatively short (6 months) time frame. This finding suggests that MD1003 has some selective efficacy when progression is ongoing. Further to this, it should be noted that the frequency of patients with progressive MS was higher in the placebo (50%) than in the MD1003 group (31%), which might have negatively influenced the results of our study. The MD1003 group had a higher proportion of patients on natalizumab or methylprednisolone than had the placebo group. Since it is thought to promote remyelination \[[@CR27]\], we cannot exclude a potential influence of natalizumab on the results of our study. However, that influence would have been likely very limited, given the low proportion of patients treated with natalizumab (13.8% in the MD1003 group and 3.6% in the placebo group) and the fact that the treatment with natalizumab had to be introduced at least 6 months prior to the MS-ON trial. Fingolimod, which is also thought to induce remyelination \[[@CR28]\], could have had an opposite influence to that of natalizumab, since the MD1003 group had a lower proportion of patients on fingolimod (15.4%) than had the placebo group (25%).

This study also confirmed the good safety and tolerability profile of MD1003. The safety profile of MD1003 was similar to that of placebo and consistent with data from the MS-SPI study \[[@CR7]\] and the open-label pilot study \[[@CR23]\]. The incidence of MS relapse was higher in the MD1003 group (9 of 65 patients; 13.8%) than in the placebo group (1 of 28 patients; 3.6%) during the double-blind phase of the study, and was also higher in the patients newly treated with MD1003 in the extension phase (3 of 28 patients; 10.7%) than in the placebo group in the double-blind phase (1 of 28 patients; 3.6%). Others have reported an increase in MS relapse in patients treated with high-dose biotin \[[@CR29], [@CR30]\]; however, these studies used a different source and dosage of biotin than our study, which does not allow any generalization \[[@CR31]\]. Branger et al. \[[@CR32]\] reported an occurrence of relapse in five patients with progressive MS after 3--7 months of treatment with hdPB, and recommended close monitoring of lesions by MRI. In a post hoc analysis from the MS-SPI study in patients with progressive MS, the annualized MS relapse rate up to 36 months did not appear to be influenced by exposure to MD1003 \[[@CR33]\]. We believe that in the present study, the number of patients with relapse is too low to allow us to draw reliable conclusions. It should be further noted that the incidence of MS relapse decreased in patients who continued to receive MD1003 during the 6-month extension phase (4.7%) (Table [2](#Tab2){ref-type="table"}). Additional safety data from an ongoing clinical trial on MD1003 (SPI2 study) may help clarify this issue.

Conclusion {#Sec15}
==========

While the efficacy endpoints of study MS-ON were not met, signs of efficacy were apparent in the subgroup of patients with progressive disease. These data provide further evidence that the most appropriate target group for MD1003 is patients with progressive forms of MS, a population that represents a significant unmet medical need. Our study could also provide useful insights on the limitations associated with the assessment of any therapeutic agent in patients with MS-associated chronic optic neuropathy.
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